Version 1
: Received: 10 May 2023 / Approved: 10 May 2023 / Online: 10 May 2023 (09:09:13 CEST)
Version 2
: Received: 23 September 2023 / Approved: 25 September 2023 / Online: 25 September 2023 (16:46:10 CEST)
How to cite:
Zakari, S.; Ekenwaneze, C.C.; Amadi, E.C.; Ogunlana, O.O. Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer. Preprints2023, 2023050720. https://doi.org/10.20944/preprints202305.0720.v2
Zakari, S.; Ekenwaneze, C.C.; Amadi, E.C.; Ogunlana, O.O. Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer. Preprints 2023, 2023050720. https://doi.org/10.20944/preprints202305.0720.v2
Zakari, S.; Ekenwaneze, C.C.; Amadi, E.C.; Ogunlana, O.O. Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer. Preprints2023, 2023050720. https://doi.org/10.20944/preprints202305.0720.v2
APA Style
Zakari, S., Ekenwaneze, C.C., Amadi, E.C., & Ogunlana, O.O. (2023). Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer. Preprints. https://doi.org/10.20944/preprints202305.0720.v2
Chicago/Turabian Style
Zakari, S., Emmanuel C. Amadi and Olubanke O. Ogunlana. 2023 "Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer" Preprints. https://doi.org/10.20944/preprints202305.0720.v2
Abstract
Prostate cancer (PCa) is a major cause of cancer-related mortality worldwide, with a rising incidence observed over the years. The androgen receptor (AR) signaling pathway plays a pivotal role in male development and maintaining masculine characteristics. Dysregulation of AR signaling in prostate cancer can lead to disease progression and resistance to standard therapies. Understanding the intricate regulation and function of AR in both healthy and diseased states is crucial for developing effective treatment strategies. This review comprehensively explores the role of androgen receptors in prostate cancer susceptibility, disease progression, and treatment response by analyzing recent literature. An extensive search of peer-reviewed publications in major databases, including PubMed, Scopus, and Web of Science, was conducted using specific keywords related to androgen receptor, prostate cancer, disease progression, and treatment resistance. Relevant conference abstracts and clinical trial reports were also included. The review presents an overview of the role of androgen receptors in prostate cancer initiation, progression, and treatment resistance. It highlights emerging biomarkers associated with AR signaling dysregulation and their potential utility for early detection and personalized treatment approaches. Additionally, recent advances in targeting the AR pathway for novel therapeutic strategies to improve patient outcomes and overcome treatment resistance in advanced prostate cancer are discussed. The findings contribute to a comprehensive understanding of the AR signaling pathway in prostate cancer and offer insights into its multifaceted role in disease development and treatment response. They may pave the way for innovative therapeutic interventions and precision medicine approaches based on specific AR signaling profiles, enhancing patient care and reducing the burden of this lethal disease.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
25 September 2023
Commenter:
Suleiman Zakari
Commenter's Conflict of Interests:
Author
Comment:
All the initial images have replaced by new ones that drew ourselves making thw work more creative. Abstract was reconstructed to cover the review methodology and type (systematic review). Also article lenth has been reduced by removing redundant staements.
Commenter: Suleiman Zakari
Commenter's Conflict of Interests: Author